Cargando…

Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases.

By measuring peripheral drug levels in plasma, the effect of combining albumin microspheres with angiotensin II on systemic exposure to 5FU when administered by bolus injection into the hepatic artery in patients with advanced colorectal liver metastases has been assessed. The results suggest that d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goldberg, J. A., Kerr, D. J., Willmott, N., McKillop, J. H., McArdle, C. S.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1988
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246442/ https://www.ncbi.nlm.nih.gov/pubmed/3358909

Ejemplares similares

The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
por: Goldberg, J. A., et al.
Publicado: (1990)

Arteriovenous shunting in patients with colorectal liver metastases.
por: Goldberg, J. A., et al.
Publicado: (1991)

A phase I study of regional 5-fluorouracil and systemic folinic acid for patients with colorectal liver metastases.
por: Anderson, J. H., et al.
Publicado: (1992)

Angiotensin II as a potential method of targeting cytotoxic-loaded microspheres in patients with colorectal liver metastases.
por: Goldberg, J. A., et al.
Publicado: (1991)

The use of angiotensin II as a potential method of targeting cytotoxic microspheres in patients with intrahepatic tumour.
por: Goldberg, J. A., et al.
Publicado: (1991)

A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases.
por: Warren, H. W., et al.
Publicado: (1994)

A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases.
por: Howell, J. D., et al.
Publicado: (1997)

Fluorouracil (5-FU)-induced Cardiomyopathy
por: Thalambedu, Nishanth, et al.
Publicado: (2019)

Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma.
por: McArdle, C. S., et al.
Publicado: (1994)

Effect of Ketorolac on Pharmacokinetics and Pharmacodynamics of 5-Fluorouracil: In Vivo and In Vitro Study
por: Atefinezhad, Motahare, et al.
Publicado: (2022)

Can localised (19)F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response?
por: McIntyre, Dominick J. O., et al.
Publicado: (2010)

A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
por: Bathe, Oliver F, et al.
Publicado: (2009)

Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery
por: De Angelis, Paula M, et al.
Publicado: (2006)

Effect of Skimmed Milk on the Absorption and Metabolism of5-Fluorouracil (5-FU) in Animals
por: Ahmad, Maqsood, et al.
Publicado: (2012)

A unique presentation of 5-fluorouracil (5-FU) induced cerebral encephalopathy
por: Naik, Shailendra S, et al.
Publicado: (2020)

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
por: Saini, A, et al.
Publicado: (2003)

Translational Pharmacokinetic‐Pharmacodynamic Modeling and Simulation: Optimizing 5‐Fluorouracil Dosing in Children With Pediatric Ependymoma
por: Daryani, VM, et al.
Publicado: (2016)

Regional delivery of microspheres to liver metastases: the effects of particle size and concentration on intrahepatic distribution.
por: Anderson, J. H., et al.
Publicado: (1991)

Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer
por: Steber, Cole, et al.
Publicado: (2021)

Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans.
por: McDermott, B. J., et al.
Publicado: (1983)

The use of duplex sonography in the detection of colorectal hepatic metastases.
por: Leen, E., et al.
Publicado: (1991)

Clinical correlation of high activity dynamic hepatic scintigraphy in patients with colorectal cancer.
por: Hemingway, D. M., et al.
Publicado: (1992)

The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer
por: Crozier, J E M, et al.
Publicado: (2006)

Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells
por: Kim, Eun-Ji, et al.
Publicado: (2018)

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
por: Bensmaïne, M A, et al.
Publicado: (2001)

An in vivo assessment of adriamycin-loaded albumin microspheres.
por: Goldberg, J. A., et al.
Publicado: (1992)

Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma.
por: Zaniboni, A., et al.
Publicado: (1988)

Efficacy of Fractional Carbon Dioxide Laser (FCO(2)) with Intralesional 5-Fluorouracil (5-FU) in the Treatment of Keloids
por: Alhamzawi, Nabeel Kadhim
Publicado: (2021)

Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model
por: Ma, Chenhui, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability
por: Jilek, Joseph L., et al.
Publicado: (2020)

Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics
por: Hsieh, Chen-Hsi, et al.
Publicado: (2010)

The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm
por: Zafar, Amna, et al.
Publicado: (2022)

Eukaryotic translation initiation factor 3 subunit G (EIF3G) resensitized HCT116/5-Fu to 5-fluorouracil (5-Fu) via inhibition of MRP and MDR1
por: Yang, Chenggang, et al.
Publicado: (2018)

Synergistic combination of PMBA and 5-fluorouracil (5-FU) in targeting mutant KRAS in 2D and 3D colorectal cancer cells
por: Qayum, Arem, et al.
Publicado: (2022)

Addition of 5-fluorouracil to docetaxel/cisplatin does not improve survival in locoregionally advanced nasopharyngeal carcinoma
por: Fangzheng, Wang, et al.
Publicado: (2017)

Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil
por: Han, Jung Ho, et al.
Publicado: (2021)

Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma
por: Öman, Mikael, et al.
Publicado: (2021)

Transcriptomic and network pharmacology approaches revealed possible mechanisms underlying the 5-fluorouracil (5-FU)-sensitizing effect of Xuan-Fu-Hua decoction treatment on liver cancer cells
por: Luo, Wen-Zhao, et al.
Publicado: (2022)

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
por: Miura, Koh, et al.
Publicado: (2010)

A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid.
por: Anderson, J. H., et al.
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_pl812u9sevsgjht89b45ck70k1